Literature DB >> 27269044

COMT haplotypes, catecholamine metabolites in plasma and clinical response in schizophrenic and bipolar patients.

Mercedes Zumárraga1, Aurora Arrúe1, Nieves Basterreche2,3, Isabel Macías4, Ana Catalán5, Arantza Madrazo5, Sonia Bustamante5, María I Zamalloa1, Leire Erkoreka3,6, Estibaliz Gordo2, Ainara Arnaiz2, Olga Olivas7, Ariane Arroita6, Elena Marín8, Miguel A González-Torres3,5.   

Abstract

AIM: We examined the association of COMT haplotypes and plasma metabolites of catecholamines in relation to the clinical response to antipsychotics in schizophrenic and bipolar patients. PATIENTS &
METHODS: We studied 165 patients before and after four weeks of treatment, and 163 healthy controls. We assessed four COMT haplotypes and the plasma concentrations of HVA, DOPAC and MHPG.
RESULTS: Bipolar patients: haplotypes are associated with age at onset and clinical evolution. In schizophrenic patients, an haplotype previously associated with increased risk, is related to better response of negative symptoms.
CONCLUSION: Haplotypes would be good indicators of the clinical status and the treatment response in bipolar and schizophrenic patients. Larger studies are required to elucidate the clinical usefulness of these findings.

Entities:  

Keywords:  COMT; antipsychotics; bipolar disorder; haplotypes; plasma metabolites; schizophrenia; symptomatology

Mesh:

Substances:

Year:  2016        PMID: 27269044     DOI: 10.2217/pgs-2016-0022

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  2 in total

1.  Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT.

Authors:  Kathryn T Hall; Joseph Loscalzo; Ted J Kaptchuk
Journal:  Pharmacogenomics       Date:  2019-05       Impact factor: 2.533

2.  COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population.

Authors:  Hasan Mervan Aytac; Yasemin Oyaci; Pinar Cetinay Aydin; Mustafa Pehlivan; Sacide Pehlivan
Journal:  Neurosciences (Riyadh)       Date:  2022-01       Impact factor: 0.735

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.